Naito E, Ito M, Matsuura S, Saijo T, Ogawa Y, Kitamura S, Kobayashi K, Saheki T, Nishimura Y, Sakura N, Kuroda Y
Department of Pediatrics, School of Medicine, University of Tokushima, Japan.
J Inherit Metab Dis. 2002 Feb;25(1):71-6. doi: 10.1023/a:1015198103395.
Type II citrullinaemia (CTLN2) is an adult- or late childhood-onset liver disease characterized by a liver-specific defect in argininosuccinate synthetase protein. The enzyme abnormality is caused by deficiency of the protein citrin, which is encoded by the SLC25A 13 gene. Until now, however, few cases with SLC25A13 mutations have been reported in children with liver disease. We describe an infant who presented with neonatal hepatitis in association with hypergalactosaemia detected by neonatal mass screening. DNA analysis of SLC25A13 revealed that the patient was homozygous for a IVS11+1G>A mutation. This case suggests that SLC25A13 mutant should be suspected in neonatal patients with hypergalactosaemia of unknown cause.
II型瓜氨酸血症(CTLN2)是一种成人或儿童晚期发病的肝脏疾病,其特征是精氨琥珀酸合成酶蛋白存在肝脏特异性缺陷。这种酶异常是由蛋白质citrin缺乏引起的,citrin由SLC25A13基因编码。然而,迄今为止,在患有肝脏疾病的儿童中,很少有SLC25A13突变的病例报道。我们描述了一名婴儿,其通过新生儿群体筛查发现患有新生儿肝炎并伴有高半乳糖血症。对SLC25A13的DNA分析显示,该患者为IVS11+1G>A突变的纯合子。该病例表明,对于病因不明的新生儿高半乳糖血症患者,应怀疑SLC25A13突变。